MediPost FY 2025 Annual ReportBeta
MediPost annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
MediPost FY 2025 Annual Report Analysis
Business Overview
- • Total consolidated revenue KRW 70.7B, +2.9% YoY, driven by cord blood bank and stem cell therapy sales
- • Cord blood bank sales KRW 41.5B, +5.9% YoY, surpassed 330,000 family blood storage units
Management Discussion & Analysis
- • Revenue KRW 73.7B (+4.25% YoY), operating loss KRW 6.8B (-40.04%), net loss KRW 8.6B (-35.68%)
- • Cord blood bank segment revenue KRW 41.5B (+5.93%), driven by 330,000 cumulative storage cases and family cord blood multi-bag service
Risk Factors
- • USD 10% exchange rate move → ±KRW 55.7M pre-tax impact on income, down from ±KRW 1.86B prior year
- • Financial liabilities due within 1 year KRW 33.4B, up from KRW 22.8B prior year
MediPost FY 2025 Key Financial MetricsDART
Total Assets
KRW 431.6B
▲ +4.2% YoY
Operating Cash Flow
-KRW 57.1B
▼ -53.3% YoY
CapEx
KRW 2.9B
▲ +9.4% YoY
Source: KIFRS consolidated financial data from MediPost annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding